This document is a review of the 2011 guidance and provides recommendations and guidance relating to the prescribing in Wales of denosumab (Prolia) for the prevention of osteoporotic fractures in postmenopausal women, and is intended to complement NICE TA204.
|
This resource has been retired and is no longer considered an AWMSG-endorsed resource. The resource underwent an assessment for review in September 2025. At that time, members of the All Wales Prescribing Advisory Group (AWPAG) considered it appropriate to retire the resource. The content contained within the resource was considered to be out of date and, without an indication that an updated version of the resource would be of significant benefit to NHS Wales, AWPAG members considered it most appropriate for the resource to be retired at this time. If you think this resource should be reconsidered for review, please get in touch with AWTTC by emailing awttc@nhs.wales.uk. |
⇩ Prescribing of Denosumab (Prolia) in Wales: Review 893KB (PDF) |
⇩ Shared Care Protocol 896KB (PDF) |
(October 2013, Retired November 2025)